Exact Sciences Corporation Stock price

Equities

EXAS

US30063P1057

Biotechnology & Medical Research

Market Closed - Nasdaq 03:59:59 2024-03-28 pm EDT 5-day change 1st Jan Change
69.06 USD +3.26% Intraday chart for Exact Sciences Corporation +11.39% -6.65%
Sales 2024 * 2.83B Sales 2025 * 3.23B Capitalization 12.14B
Net income 2024 * -161M Net income 2025 * 4M EV / Sales 2024 * 4.82 x
Net Debt 2024 * 1.51B Net Debt 2025 * 1.09B EV / Sales 2025 * 4.09 x
P/E ratio 2024 *
-75.9 x
P/E ratio 2025 *
3,554 x
Employees 6,550
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.99%
More Fundamentals * Assessed data
Dynamic Chart
Exact Sciences Corp. Advances Development of Non-Endoscopic Oncoguard Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer CI
Transcript : Exact Sciences Corporation - Special Call
Exact Sciences Insider Sold Shares Worth $287,500, According to a Recent SEC Filing MT
Transcript : Exact Sciences Corporation Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-04-2024 01:30 PM
Exact Sciences Insider Sold Shares Worth $356,302, According to a Recent SEC Filing MT
Exact Sciences Insider Sold Shares Worth $305,963, According to a Recent SEC Filing MT
Transcript : Exact Sciences Corporation, Q4 2023 Earnings Call, Feb 21, 2024
Earnings Flash (EXAS) EXACT SCIENCES Reports Q4 Revenue $646.9M, vs. Street Est of $639.7M MT
Exact Sciences Corporation Provides Earnings Guidance for the first quarter and Year 2024 CI
Exact Sciences' Q4 Loss Narrows, Revenue Increases; Sets 2024 Revenue Forecast MT
Exact Sciences Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Exact Sciences Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 11:15 AM
Exact Sciences Sees 17% Growth in Q4 Revenue MT
Exact Sciences Corporation Announces Jeff Elliott Plans to Step Down as Chief Financial Officer in 2024 CI
Exact Sciences Corporation Provides Revenue Guidance for the Year Ended December 31, 2023 and 2024 CI
More news

Latest transcript on Exact Sciences Corporation

1 day+5.24%
1 week+13.56%
Current month+22.39%
1 month+25.04%
3 months-7.01%
6 months+1.81%
Current year-4.83%
More quotes
1 week
60.25
Extreme 60.25
71.62
1 month
56.07
Extreme 56.07
71.62
Current year
56.05
Extreme 56.05
76.60
1 year
56.05
Extreme 56.05
100.77
3 years
29.27
Extreme 29.27
140.18
5 years
29.27
Extreme 29.27
159.54
10 years
4.67
Extreme 4.67
159.54
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 09-03-17
Director of Finance/CFO 46 16-06-19
Chief Tech/Sci/R&D Officer - 18-03-05
Members of the board TitleAgeSince
Director/Board Member 59 14-12-31
Chief Executive Officer 58 09-03-17
Director/Board Member 68 20-04-21
More insiders
Date Price Change Volume
24-03-28 69.06 +3.26% 5 453 102
24-03-27 66.88 +2.51% 1,710,772
24-03-26 65.24 +2.32% 1,920,618
24-03-25 63.76 +2.67% 1,803,464
24-03-22 62.1 +0.16% 1,011,708

Delayed Quote Nasdaq, March 28, 2024 at 02:34 pm EDT

More quotes
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, and OncoExTra Test. The Company’s flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
66.88 USD
Average target price
88.49 USD
Spread / Average Target
+32.31%
Consensus
  1. Stock
  2. Equities
  3. Stock Exact Sciences Corporation - Nasdaq